The approval is based on IXCHIQ®’s final pivotal Phase 3 data, published in The Lancet, which included more than 4,000 participants and demonstrated that a single dose of the live-attenuated ...

The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years and older, but Bavarian Nordic’s Vimkunya is the first chikungunya vaccine ...

Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, commented, “This latest approval is a further recognition of IXCHIQ ® ’s strong product profile and the medical need for a ...

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing chikungunya disease in adults only, although, it is in clinical ...

The French pharma company – best known for its COVID-19 jab and recent approval for the world's first chikungunya vaccine Ixchiq – is paying €10 million upfront for a stake in LimmaTech's ...

The agency approved the company's chikungunya vaccine, Ixchiq, for use in people 18 years of age and older. Late-stage trial data show the vaccine "induces a rapid and strong immune response ...

Having an edge over competitors in the market place by having a superior product, as well as promoting it and distributing it more effectively. Gaining a competitive edge may be a result of correctly ...

At present, streaming OTT box/sticks & shrewd TVs are the two most normal gadget types for streaming. However, inside every one of these gadget classifications is a few brands battling for a portion ...

After hours: February 12 at 6:14:33 PM EST Loading Chart for VALN ...